--- title: "Eli Lilly will file its obesity pill Foundayo for sleep apnea after a 44% cut in severity" description: "A 43.8% cut in breathing interruptions gives Lilly's pill a shot at a diagnosed-disease budget, and the company commits to an FDA filing by year-end. Novo Nordisk's rival outcomes strategy failed at the same heart conference." publisher: "The Inference" section: "Health" published: 2026-11-10T16:13:05.897Z modified: 2026-11-10T16:13:05.897Z canonical: https://theinference.org/article/eli-lilly-will-file-its-obesity-pill-foundayo-for-sleep-apnea-after-a-44-cut-in-severity language: en keywords: "Pharma, Obesity Drugs, Clinical Trials, Drug Pricing, FDA" --- # Eli Lilly will file its obesity pill Foundayo for sleep apnea after a 44% cut in severity > A 43.8% cut in breathing interruptions gives Lilly's pill a shot at a diagnosed-disease budget, and the company commits to an FDA filing by year-end. Novo Nordisk's rival outcomes strategy failed at the same heart conference. [Eli Lilly](https://theinference.org/markets/companies/eli-lilly) said Monday that [Foundayo, its once-daily obesity pill](https://theinference.org/article/lilly-sells-a-modelled-57-diabetes-risk-cut-on-foundayo-just-as-its-drug-prices-fall), [significantly cut the severity of obstructive sleep apnea in a Phase 3 trial](https://finance.yahoo.com/healthcare/articles/lillys-foundayo-orforglipron-significantly-reduced-143000435.html), and the company committed to file with the FDA for that use by the end of 2026 [1]. The result moves the pill toward a diagnosed disease with its own spending, away from weight-loss benefits that insurers have been trimming. Lilly's shares rose about 3% on the news as [Jefferies](https://theinference.org/markets/companies/jefferies) [set a street-high $1,700 price target](https://finance.yahoo.com/markets/stocks/articles/eli-lilly-stocks-rise-3-181701651.html) [3]. ## Why a sleep apnea label changes who pays Obstructive sleep apnea is interrupted breathing during sleep, when the airway narrows or collapses; it affects an estimated 936 million adults worldwide, most never diagnosed, and is linked to hypertension, heart failure and stroke [1]. The mechanism runs through weight: patients in Lilly's ATTAIN-OSA trial lost about 11% of their body weight, and the airway collapses less when the fat around it shrinks [1][2]. Foundayo is a GLP-1, the drug class behind Ozempic, Wegovy and Zepbound, and [reduced breathing interruptions per hour, the standard severity measure, by 43.8%](https://www.cnbc.com/2026/11/09/eli-lilly-foundayo-sleep-apnea-trial.html) in patients not using a CPAP machine, against 6.3% on placebo; roughly a third of that group reached remission or mild disease [1][2]. *Chart: **Foundayo cut breathing interruptions 43.8% where placebo managed 6.3%** Bars comparing the percent change in apnea-hypopnea index at 52 weeks in ATTAIN-OSA: Foundayo reduced it 43.8% versus 6.3% on placebo in patients not using CPAP, and 27.5% versus 3.0% in patients on CPAP.* *Percent change in apnea-hypopnea index, events of interrupted or shallow breathing per hour, at 52 weeks in Lilly's ATTAIN-OSA Phase 3 program, efficacy estimand. Source: Eli Lilly press release, November 9, 2026 [1]. [1]* Payers fund drugs for diagnosed diseases out of a medical budget; weight-loss prescriptions fall under a benefit many insurers have been cutting. Zepbound, Lilly's injection, won [the first FDA approval for sleep apnea](https://finance.yahoo.com/m/363c8fec-d17a-3593-8227-dab89791fbc9/eli-lilly-s-weight-loss-pill.html) in December 2024, and Foundayo would be Lilly's second drug for the same condition [6]. The edge over [Novo Nordisk](https://theinference.org/markets/companies/novo-nordisk)'s own oral Wegovy, as Barron's frames it, is this label breadth [6]. ## Novo's rival strategy failed at the same conference At the same American Heart Association meeting, Novo Nordisk's ziltivekimab [cut the inflammation marker IL-6 by 76%](https://www.techtimes.com/articles/330262/20261108/novo-nordisk-zeus-trial-cut-inflammation-76-zero-reduction-heart-attacks-across-6376-patients.htm) across 6,376 patients and produced a hazard ratio of 0.99 for heart attacks and strokes, essentially nothing [4]. Novo halted two follow-up trials for futility and wrote the drug down in its third quarter [4]. Lilly is stacking disease labels instead of betting on outcomes evidence. ## The risk numbers a payer reads first Adverse-event discontinuations ran 12.2% versus 3.8% on placebo among patients not using CPAP, the number payers will read first [1]. The FDA this week also [required a vision-loss warning across GLP-1 labels](https://www.investing.com/news/stock-market-news/fda-requires-visionloss-warning-on-novo-nordisk-and-eli-lilly-glp1-drugs-5012866), including Lilly's and Novo's [5]. The FDA decision is the easy part; whether insurers pay is what decides the market. A year-end submission is near-certain and priced, but the label only converts into revenue if insurers treat sleep apnea as a covered indication. That decision likely lands over 2027, when payers set their benefit designs. ## Takeaway Foundayo cut sleep apnea severity 43.8% versus 6.3% on placebo, and Lilly will file it for the indication by year-end; the fight that decides the drug's value is with insurers, not the FDA. ## Sources 1. [PR Newswire via Yahoo Finance, Lilly's Foundayo (orforglipron) significantly reduced obstructive sleep apnea severity, 9 November 2026](https://finance.yahoo.com/healthcare/articles/lillys-foundayo-orforglipron-significantly-reduced-143000435.html) 2. [CNBC, Eli Lilly's Foundayo obesity pill eases sleep apnea in late-stage trial, 9 November 2026](https://www.cnbc.com/2026/11/09/eli-lilly-foundayo-sleep-apnea-trial.html) 3. [GuruFocus via Yahoo Finance, Eli Lilly Stocks Rise 3.40% as Jefferies Sets Street-High $1,700 Target, 9 November 2026](https://finance.yahoo.com/markets/stocks/articles/eli-lilly-stocks-rise-3-181701651.html) 4. [Tech Times, Novo Nordisk ZEUS Trial Cut Inflammation 76%; Zero Reduction in Heart Attacks Across 6,376 Patients, 8 November 2026](https://www.techtimes.com/articles/330262/20261108/novo-nordisk-zeus-trial-cut-inflammation-76-zero-reduction-heart-attacks-across-6376-patients.htm) 5. [Investing.com (Reuters), FDA requires vision-loss warning on Novo Nordisk and Eli Lilly GLP-1 drugs, 9 November 2026](https://www.investing.com/news/stock-market-news/fda-requires-visionloss-warning-on-novo-nordisk-and-eli-lilly-glp1-drugs-5012866) 6. [Barron's via Yahoo Finance, Eli Lilly's Weight-Loss Pill Shows Sleep Apnea Benefits. Can It Gain on Novo?, 9 November 2026](https://finance.yahoo.com/m/363c8fec-d17a-3593-8227-dab89791fbc9/eli-lilly-s-weight-loss-pill.html) --- Eli Lilly will file its obesity pill Foundayo for sleep apnea after a 44% cut in severity — The Inference. Canonical: https://theinference.org/article/eli-lilly-will-file-its-obesity-pill-foundayo-for-sleep-apnea-after-a-44-cut-in-severity